Mark Lackner
Known title: Chief Scientific OfficerCIK: 0001777413
Associated companies
Transaction History
| ZNTL | ▼ Sell | Open Market | 14,368 | $25K | 2/3/2025 | View on chart |
| ZNTL | ▲ Buy | Grant | 335,907 | $0 | 2/3/2025 | View on chart |
| ZNTL | ▼ Sell | Open Market | 4,411 | $14K | 1/2/2025 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,585 | $18K | 2/2/2024 | View on chart |
| ZNTL | ▲ Buy | Grant | 141,000 | $0 | 2/1/2024 | View on chart |
| ZNTL | ▲ Buy | Grant | 40,000 | $0 | 1/2/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.